Glioblastoma multiforme is the most common and malignant primary brain tumor, with a high recurrence rate and a five-year survival rate of less than 5% (1). Nearly 50% of glioblastomas originate in the frontal or temporal lobes of the brain (1). Glioblastomas are the most aggressive form of cancer, highlighting the importance of relevant human patient-derived cell models for advancing research into characteristics and treatment of this disease. SF126 is a patient-derived glioblastoma cell line originating from a frontal lobe tumor (2). SF126 cells do not express the glial markers GFAP or glutamine synthetase but are positive for laminin and fibronectin expression in early passages, suggestive of proliferative or transformed mesenchymal cells of glioblastoma (2). SF126 cells exhibit hypertriploidy and fibroblastic morphology in culture and are non-tumorigenic in athymic mice (2). Source:The SF126 glioblastoma cell line was derived from the left frontal lobe tumor of a 50-year-old female patient (2).Research Category:Cancer
Application: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.